Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Single-Arm Phase II Study of ALIMTA in Combination With Oxaliplatin as First-Line Therapy in Advanced Gastric Carcinoma

NCT00192088 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00192088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00192088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Single-Arm Phase II Study of ALIMTA in Combination With Oxaliplatin as First-Line Therapy in Advanced Gastric Carcinoma
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2004
Completion date
May 31, 2006
Enrollment
43
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric carcinoma